REVEAL AF STUDY ICM EVIDENCE FOR SUSPECTED AF
REVEAL AF Study for insertable cardiac monitor use in patients at high risk for atrial fibrillation and stroke
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
REVEAL AF Study for insertable cardiac monitor use in patients at high risk for atrial fibrillation and stroke
The REVEAL AF Study demonstrates the need for continuous, long-term monitoring with Reveal LINQ™ insertable cardiac monitoring (ICM) in patients at high risk for atrial fibrillation and stroke.
There was no significant difference in detection rates between patients with CHADS2 2, 3, and 4 or more.
Primary
Secondary
Reiffel JA, Verma A, Kowey PR, et al. High Incidence of Previously Unknown (“Silent”) Atrial Fibrillation in Patients at High Risk for Atrial Fibrillation and Stroke: Primary Results from the REVEAL AF Study. Abstract presented at Heart Rhythm Society Annual Scientific Sessions. 2017.